DEA Hearing Schedule Keeps Cannabis Rescheduling Uncertainty Alive
Cannabis industry team reviewing rescheduling strategy and risk
Federal cannabis rescheduling is moving again, but the process remains legally messy. Marijuana Moment reports that DEA Chief Administrative Law Judge Derek Julius issued a testimony schedule for the next phase of the cannabis rescheduling hearing, which is set to begin on June 29, 2026. Under the current DEA framework, only opponents of broader Schedule III reform were selected to participate, while the government will present first. For operators, investors, lenders, compliance teams, retailers, and manufacturers, this is another reminder that federal reform can create opportunity and uncertainty at the same time.
Quick facts
• The DEA cannabis rescheduling hearing is scheduled to begin on June 29, 2026
• The hearing is expected to conclude no later than July 15, 2026
• The government is scheduled to present first on June 29
• National Drug and Alcohol Screening Association is scheduled for July 2
• Smart Approaches to Marijuana is scheduled for July 6
• DUID Victim Voices is scheduled for July 7
• Kenneth Finn, M.D. is scheduled for July 8
• Tennessee Bureau of Investigation is scheduled for July 10
• Phillip A. Drum, PharmD is scheduled for July 13
• The states of Nebraska, Idaho, Indiana, and Louisiana are scheduled for July 14
• The universal operator lesson is simple: cannabis rescheduling may create tax and capital upside, but court and agency process can still change timing
If rescheduling uncertainty is affecting your growth plan, complete our quick Cannashield intake form so you can map tax, compliance, financing, and insurance exposure before federal timing changes the market again.
Why the hearing schedule matters
The hearing schedule matters because it gives the industry a concrete timeline for the next phase of broader cannabis rescheduling. The federal government has already moved FDA approved cannabis products and state licensed medical cannabis into Schedule III. The current hearing process is focused on whether cannabis more broadly should move from Schedule I to Schedule III.
That distinction matters. Operators may hear “Schedule III” and assume the issue is settled. It is not. The federal process now has multiple tracks, including an already issued medical focused order, a broader evidentiary hearing, litigation challenging parts of the reform, and continued agency questions around registration, taxes, drug testing, and public access.
This is why the hearing is important even if the final result is not immediate. Federal cannabis policy is still being built in real time.
Why the participant list is controversial
One of the biggest concerns is who gets to participate. Marijuana Moment reports that only opponents of the broader reform were selected under the current DEA framework. No reform supporters who sought to participate were invited. That creates a public legitimacy issue even if the hearing technically follows the agency’s procedural rules.
For operators and investors, the practical issue is not whether the hearing feels fair. The practical issue is whether the process creates delay, litigation, or a record that affects final federal action. If opponents dominate the hearing record, reform supporters may continue challenging the process. If DEA defends the proposal weakly, uncertainty could grow. If the agency moves quickly and survives litigation, the industry may get more clarity.
This is the universal operator lesson. Federal reform does not become bankable until the process survives the challenges around it.
If uncertainty around 280E planning, Schedule III timing, or investor communication is affecting how you plan, complete our Cannashield questionnaire to pressure test your exposure before federal assumptions become outdated.
Why operators should stay careful on tax planning
The biggest business issue remains tax planning. Schedule III could remove the federal 280E burden for businesses covered by the reform because 280E applies to trafficking in Schedule I or Schedule II controlled substances, not Schedule III substances. That is why operators and investors are watching rescheduling closely.
But businesses should be careful with timing. The medical focused order may create immediate benefits for some state licensed medical operations, while broader adult use relief may depend on future rulemaking, IRS guidance, litigation outcomes, and how businesses are structured. Companies that operate in both medical and adult use channels may need careful entity level and activity level analysis before assuming full tax relief.
A tax plan built on hope can become dangerous. A tax plan built on scenarios is more useful.
Cannabis team planning for federal rescheduling business impact
Why lenders and investors should watch the record
Lenders and investors should watch the hearing because it may affect valuation, cash flow assumptions, debt service, and capital access. If Schedule III relief becomes more durable, cannabis businesses could look stronger on paper because federal tax deductions may become available to more operations. If the process slows, gets narrowed, or faces a court stay, those same projections may need revision.
This is also important for public companies and multistate operators that are already restructuring around medical cannabis, DEA registration, and major exchange access. A hearing dominated by opponents does not automatically block reform, but it does add another layer of uncertainty.
If you need to organize tax, licensing, financing, and insurance records before the hearing record develops, use the Cannashield intake form to identify weak points and build a cleaner planning file.
You might also like
Conclusion
The DEA hearing schedule gives the cannabis industry a new federal timeline, but not final certainty. The process begins June 29, runs through mid July, and gives opponents of broader rescheduling a central role in the hearing record. That keeps federal reform active, but legally complicated.
For operators, investors, lenders, retailers, manufacturers, and compliance teams, the message is simple. Plan for Schedule III upside, but do not build your entire strategy on one outcome. Federal reform is moving, yet timing, litigation, tax guidance, DEA registration, and agency procedure still matter.
Educational note: This article is for education only and is not legal, regulatory, tax, financial, investment, employment, or insurance advice.
What To Do This Week
• Track the June 29 hearing start and the July 15 outside deadline
• Review whether your tax projections depend on broad Schedule III relief
• Separate medical operations from adult use exposure in financial planning
• Watch for IRS guidance, DEA registration updates, and litigation developments
• Review lender and investor materials for overconfident rescheduling assumptions
• Build a short internal memo on best case, delayed case, and adverse case federal scenarios
FAQ
When does the DEA cannabis rescheduling hearing start?
The hearing is scheduled to begin on June 29, 2026.
When is the hearing expected to end?
The Federal Register notice says the hearing will conclude no later than July 15, 2026.
Who is scheduled to present first?
The government is scheduled to present first on June 29.
Why is the participant list controversial?
Marijuana Moment reports that only opponents of broader Schedule III reform were selected to participate under the current DEA framework.
Does this hearing mean cannabis is already fully Schedule III?
No. State licensed medical cannabis and FDA approved cannabis products have already moved to Schedule III, but the broader cannabis rescheduling issue is still moving through this hearing process.
What is the biggest operator takeaway?
Schedule III may create major tax and capital benefits, but operators need scenario planning because the process remains legally and procedurally uncertain.
SOURCES
Marijuana Moment, DEA Judge Sets Testimony Schedule For Marijuana Rescheduling Hearing Starting Next Week
https://www.marijuanamoment.net/dea-judge-sets-testimony-schedule-for-marijuana-rescheduling-hearing-starting-next-week/
DEA, Marijuana Rescheduling Regulatory Actions
https://www.dea.gov/marijuana-rescheduling-regulatory-actions
Federal Register, Schedules of Controlled Substances: Rescheduling of Marijuana
https://www.federalregister.gov/documents/2026/04/28/2026-08177/schedules-of-controlled-substances-rescheduling-of-marijuana
A DEA administrative law judge issued the testimony schedule for the next phase of the federal cannabis rescheduling hearing, which begins June 29 and is expected to conclude by July 15. The bigger lesson is that Schedule III reform remains active, but operators still need to plan around litigation, agency procedure, tax timing, and federal uncertainty.